Skip to main content
Clinical Trials/NCT02406105
NCT02406105UnknownPhase 2

An Evaluation of Effectiveness and Toxicity of CyberKnife Based Functional Radiosurgery for Parkinson Disease Patients Suffering From Tremor and Its Implementation in Poland

Maria Sklodowska-Curie National Research Institute of Oncology1 site in 1 country27 target enrollmentStarted: January 2015Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 2
Enrollment
27
Locations
1
Primary Endpoint
Tremor reduction evaluated using Unified Parkinson's Disease Rating Scale

Study Overview

Brief Summary

Clinical objective of the study is estimation of effectiveness and safety of Cyber Knife based functional radiosurgery for Parkinson disease patients suffering from tremor.

Detailed Description

Basic treatment patients with Parkinson's disease (PD - Parkinson's disease) or essential tremor (ET - essential tremor) is a pharmacotherapy. In the case of lack of its effectiveness, the gold standard procedure is deep brain stimulation (DBS). Despite the proven efficacy, still remains a group of patients not eligible for this treatment. in such cases, ablation within the deep structures of the brain (thalamotomy, subthalamotomy, pallidotomy) can be considered.

Thermoablation and radiosurgery (SRS - Stereotactic radiosurgery) are used: SRS is prefered for patients who are not candidates for invasive procedures.

27 patients will be enrolled in this study. All patients will be immobilized in thermoplastic masks and planned (RT) on the base of CT/MRI fusion.

The initial total dose in the target volume (thalamic nuclei complex - VoP and VoA ) will be 70 Gy given in one fraction. The dose will be escalated every 5 Gy and the treatment effect and possible side effects will be evaluated. Dose escalation will be finished at a dose at which the effect of treatment will be satisfactory, or if side effects are unacceptable. The highest dose tested dose will be 110 Gy. Three patients will be irradiated with particular doses and observed at least 3 moths; then study will be continued.

Patients will be controlled 3, 6, 9, 12, 18 months after treatment completion and, next every each 6 months. Neurologic and neuropsychologic status, local effect (MRI ) and eventual toxicity will be checked during follow-up (FU).

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Idiopatic Parkinson Disease (PD)
  • Lack of effective pharmacotherapy
  • Lack of possibilities of qualifications to DBS (deep brain stimulation) procedure
  • Informed consent for participation in the study and for radiotherapy

Exclusion Criteria

  • Age under 18
  • Pregnancy
  • Other than PD induced tremor
  • Dementia, psychosis.
  • Poor performance status
  • Atrophic cerebral changes, structural changes in basal nuclei
  • Lack of informed consent.

Arms & Interventions

Radiosurgical thalamotomy

Experimental

Cyber Knife based functional radiosurgical thalamotomy, photons 6MV, single dose 70-110 Gy

Intervention: Radiosurgical thalamotomy (Radiation)

Radiosurgical thalamotomy

Experimental

Cyber Knife based functional radiosurgical thalamotomy, photons 6MV, single dose 70-110 Gy

Intervention: CyberKnife (Drug)

Outcomes

Primary Outcomes

Tremor reduction evaluated using Unified Parkinson's Disease Rating Scale

Time Frame: 1 year

Tremor reduction will be evaluated using Unified Parkinson's Disease Rating Scale (UDPRS)

Secondary Outcomes

  • Safety of treatment (evaluated using RTOG/EORTC Acute Radiation Morbidity Scoring Criteria and Late Radiation Morbidity Scoring Schema)(1 year)
  • Evaluation of the value of magnetic resonance spectroscopy as a tool for metabolites proportions changes after PD radiosurgery (spectra of metabolites in irradiated volume)(2 years)
  • Implementation of CyberKnife radiosurgery for Parkinson disease patients not eligible for other treatment modality(2 years)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials